Naltrexone for opioid use disorders a review of clinical effectiveness, cost-effectiveness, and guidelines
The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral na...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 4, 2017, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The Food and Drug Administration in the U.S. approved naltrexone (XR-NTX) in 2010, however, in Canada extended-release naltrexone is only available through the Health Canada's Special Access Programme or for research. Given the relative novelty of XR-NTX, its effectiveness compared with oral naltrexone remains unclear, despite the potential for higher adherence. In addition, the clinical and cost effectiveness of both these options is relevant because having multiple treatment options can support stakeholders to treat opioid dependence. This review assesses the clinical effectiveness, cost-effectiveness and guidelines for oral and injectable naltrexone to treat opioid dependence to inform policy-making in Canada to address the increasing burden of opioid use disorders |
|---|---|
| Physical Description: | 1 PDF file (38 pages) illustrations |